Do results of exploratory endpoints need to be reported within the same clinical study report as the primary and secondary endpoint data?
Printable View
Do results of exploratory endpoints need to be reported within the same clinical study report as the primary and secondary endpoint data?
Good idea to read the ICH E3 guidance on CSR. "11.4.7 Efficacy Conclusions
The important conclusions concerning efficacy should be concisely described, considering primary and secondary end points, pre-specified and alternative statistical approaches and results of exploratory analyses."
There is a also very good ICH E3 Q & A document (2012) that might be useful.
For instance a reply to this Q: Specifically, what are the options for submission of data for topics such as pharmacokinetics, pharmacodynamics, pharmacogenomics (genomic markers), gene therapy, stem cells, biomarkers, devices, Quality of Life, Assay Validation, Data Monitoring/Review Committees, Electrocardiogram, other Safety reports, images, pictures/scans, diagnostic tests for individualized therapy, and patient-reported outcomes?